AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update

AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update Initiating CEO transition plan Divesting Intrarosa® and Vyleesi® 2020 financial guidance reflects reduction in annual operating expenses of more than $100M and a return to positive adjusted EBITDA WALTHAM, Mass., January 9, 2020 – AMAG Pharmaceuticals, Inc. (NASDAQ:… More

AMAG PHARMACEUTICALS AWARDS FOUR GRANTS TO SUPPORT PRETERM BIRTH AND PREECLAMPSIA RESEARCH

WALTHAM, Mass. December 18, 2019 – As part of the company’s ongoing support of research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has awarded four grants totaling nearly $300,000 to independent researchers in the field. “Preterm birth is the leading cause of infant morbidity and… More

AMAG PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Commercial products achieve strong revenue and market share performance VyleesiTM (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available for at-risk pregnant women Conference call scheduled for 8:00 a.m. ET today WALTHAM, MA (November 1, 2019) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results… More

AMAG REPORTS ON FDA ADVISORY COMMITTEE MEETING FOR MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION)

Company to Comment During Third Quarter Financial Results Conference Call on Friday, November 1, 2019, at 8:00 a.m. ET WALTHAM, Mass., October 29, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the U.S. Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to better understand and interpret the PROLONG (Progestin’s… More

AMAG PHARMACEUTICALS ANNOUNCES THE PUBLICATION OF THE PROLONG TRIAL EVALUATING 17-OHPC in the American Journal of Perinatology

WALTHAM, Mass. October 25, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) were published online in the American Journal of Perinatology. PROLONG was a randomized, double-blind, placebo-controlled clinical trial evaluating 17-OPHC (17-α-hydroxyprogesterone caproate or Makena®) in patients with a history of a prior spontaneous singleton preterm… More

AMAG PHARMACEUTICALS ANNOUNCES THE PUBLICATION OF THE PHASE 3 VYLEESI™ (BREMELANOTIDE INJECTION) DATA IN Obstetrics & Gynecology

The RECONNECT Studies Demonstrated a Clinically Meaningful and Statistically Significant Improvement in the Co-Primary Endpoints of Desire and Associated Distress WALTHAM, Mass. October 11, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and its voluntary open-label one year extension studies were published in… More

AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

Paul Fonteyne and David Johnson Join Board of Directors WALTHAM, Mass., October 8, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP (“Caligan”). As part of this agreement, the Board of Directors has appointed Paul Fonteyne, former Chief Executive Officer of Boehringer… More

AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

WALTHAM, Mass., September 25, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, October 3, 2019. Ted Myles, chief financial officer, will participate in a fireside chat at 10:40 a.m. ET. A live audio webcast will be accessible through the Investors section of the… More

AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders

Details Caligan Partners’ Reckless Business Ideas and Inexperienced Director Nominees Urges Shareholders to Sign and Return AMAG’s GREEN Consent Revocation Card WALTHAM, Mass., Sept. 23, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG” or the “Company”) today announced that it filed a definitive consent revocation statement with the U.S. Securities and Exchange Commission… More

AMAG Sends Letter to Shareholders

Urges Shareholders Take No Action On Caligan Consent Solicitation WALTHAM, Mass., Sept. 12, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today issued the following letter, which will be mailed to its shareholders. AMAG’s Board urges all AMAG shareholders to refrain from taking any action (including returning any consent card sent… More